ArticleClinical and translational medicine2021

Oncogenic PAX6 elicits CDK4/6 inhibitor resistance by epigenetically inactivating the LATS2-Hippo signaling pathway.

Yi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.